Search results
Results From The WOW.Com Content Network
Get breaking Business News and the latest corporate happenings from AOL. From analysts' forecasts to crude oil updates to everything impacting the stock market, it can all be found here.
Stock indexes drifted to a mixed finish on Wall Street as some heavyweight technology and communications sector stocks offset gains elsewhere in the market. The S&P 500 slipped less than 0.1% ...
Microcrystalline Cellulose Market to Reach USD 1,794.1 Million by 2033, Driven by Growing Demand in Pharmaceuticals, Food & Beverages, and Industrial Applications | Future Market Insights, Inc. NEWARK, Del, Dec. 16, 2024 (GLOBE NEWSWIRE) -- The global microcrystalline cellulose market is projected to experience substantial growth, with a ...
Microcrystalline cellulose (MCC) is a term for refined wood pulp and is used as a texturizer, an anti-caking agent, a fat substitute, an emulsifier, an extender, and a bulking agent in food production. [1] The most common form is used in vitamin supplements or tablets.
Price Action: CRVS stock is down 36.80% at $4.67 at the last check on Wednesday. Read Next: United Microelectronics Signs Landmark Renewable Energy Deal with Fengmiao I Offshore Wind Farm, Stock Gains
Quark Pharmaceutical signed a collaboration agreement with the University of Michigan for the development of proprietary SiRNA for noise-induced hearing loss. The collaboration includes studies on different SiRNA candidate drugs inhibiting Quark's proprietary target genes for the prevention and treatment of hearing loss caused by acoustic trauma.
The most common way to prepare cellulose acetate phthalate consists of the reaction of a partially substituted cellulose acetate (CA) with phthalic anhydride in the presence of an organic solvent and a basic catalyst. The organic solvents widely used as reaction media for the phthaloylation of cellulose acetate are acetic acid, acetone, or ...
Vertex Pharmaceuticals (NASDAQ: VRTX) fell by 13% on Dec. 19, when the rare-disease drug developer reported some lackluster results from a late-stage clinical trial. But far from being a reason to ...